ICML 2019 | Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the analysis of the clinical determinants for the safety and effiacy of camidanlumab tesirine (Cami-T; ADCT-301) for relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.